CSE1L and non-small cell lung carcinoma: This suggests WT p53 NSCLC cells that express high levels of CSE1L and DREAM target genes may be more susceptible to targeting CSE1L-mediated RB-DREAM pathway with HDAC1/2 specific inhibitors.